Placenta accreta spectrum: We can do better.

Aust N Z J Obstet Gynaecol

Westmead Institute for Maternal and Fetal Medicine, Women's and Newborn Health, Westmead Hospital, Sydney, Australia.

Published: June 2022

Background: Placenta accreta spectrum (PAS) has a high risk of maternal morbidity, and requires meticulous antenatal and peripartum management.

Aims: To compare the management and outcomes of PAS between women with and without antenatally suspected disease, and to evaluate the effect of multidisciplinary team (MDT) management.

Materials And Methods: A retrospective cohort study identified all hysterectomy specimens with a histopathological diagnosis of PAS in the Western Sydney Local Health District between January 2006 and December 2019, and analysed each patient's clinical course.

Results: Seventy patients had PAS diagnosed on hysterectomy specimens, of which 38 cases (54%) were antenatally suspected. Women with suspected PAS were more likely to have a previous caesarean section (100% vs 68%, P < 0.001), placenta praevia (92% vs 56%, P < 0.001) and anterior placenta (95% vs 66%. P = 0.011). Suspected PAS was associated with less maternal blood loss (median blood loss 2000 mL vs 4000 mL, P < 0.001), fewer red blood cell transfusions (median four units vs nine units, P < 0.001), and shorter intensive care or high dependency unit admission (mean stay one day vs three days, P = 0.037). There were no significant differences in other maternal morbidities. MDT management was associated with a clinically significant reduction in maternal blood loss (1500 mL vs 2520 mL, P = 0.09) and red blood cell transfusion (one unit vs six units, P = 0.04). The mean gestation of delivery was 37 weeks in both groups with no differences in neonatal morbidity.

Conclusions: Both antenatally diagnosed PAS and MDT management reduced blood loss and blood transfusion. Elective delivery at 37 weeks gestation reduces the neonatal risks of preterm delivery.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajo.13471DOI Listing

Publication Analysis

Top Keywords

placenta accreta
8
accreta spectrum
8
antenatally suspected
8
hysterectomy specimens
8
pas
5
spectrum better
4
better background
4
background placenta
4
spectrum pas
4
pas high
4

Similar Publications

We Should Perform a Systematic Evaluation of the Placenta.

J Ultrasound Med

January 2025

Department of Obstetrics and Gynecology and Reproductive Sciences, McGovern Medical School, University of Texas, Health Science Center at Houston (UTHealth), Houston, Texas, USA.

Despite its critical importance, the placenta receives substantially less attention during obstetric ultrasound examinations compared to the fetus. The evaluation of the placenta is typically limited to determining its location within the uterus, particularly its relationship to the cervix. Abnormal placenta findings are the result of gross anomalies identified by chance during obstetric examinations, rather than from a systematic evaluation.

View Article and Find Full Text PDF

Background: Bladder injury during cesarean delivery (CD) in pregnant women with severe placenta accreta spectrum (PAS) disorders mostly occurs in the dissection of vesico-uterine space. Placental MRI may help to assess the risk of bladder injury preoperatively.

Purpose: To identify the high-risk MRI signs of bladder injury during CD in women with severe PAS.

View Article and Find Full Text PDF

Background: Placenta accreta spectrum (PAS) disorder is a fatal condition responsible for obstetric haemorrhage, which contributes to increased feto-maternal morbidity and mortality. The main contributing factor is a scarred uterus, often from a previous cesarean delivery, myomectomy, or uterine instrumentation. The occurrence of PAS in an unscarred uterus is extremely rare, with only anecdotal cases reported so far in the literature.

View Article and Find Full Text PDF

Placenta accreta represents a spectrum of adherent placental anomalies and is an atypical invasion of the placenta. The major predisposing factor is a prior cesarean delivery. Placenta previa is considered an additional risk factor.

View Article and Find Full Text PDF

Despite the increasing number of placenta accreta spectrum (PAS) cases in recent years, its impact on neonatal outcomes and respiratory morbidity, as well as the underlying pathogenetic mechanism, has not yet been extensively studied. Moreover, no study has yet demonstrated the effectiveness of antenatal corticosteroid therapy (CT) for the prevention of respiratory distress syndrome (RDS) in newborns of mothers with PAS at the molecular level. In this regard, microRNA (miRNA) profiling by small RNA deep sequencing and quantitative real-time PCR was performed on 160 blood plasma samples from preterm infants (gestational age: 33-36 weeks) and their mothers who had been diagnosed with or without PAS depending on the timing of the antenatal RDS prophylaxis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!